NDA 214787 · Gilead Sciences INC
Veklury
Remdesivir · Intravenous · SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Oct 22, 2020
Approved uses
5
Original approval plus efficacy supplements
Registered trials
104
51 Phase 3, 16 recruiting
FAERS reports
13,295
11,170 serious, 3,305 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 29, 2026.
VEKLURY is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) who are [see Clinical Studies (14) ] : Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. VEKLURY is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) who are: Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. ( 1 )
Mechanism: Remdesivir is an antiviral drug with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 28, 2024 Supplement 26 · Efficacy · priority review LabelLetterSummary Review
- Jul 13, 2023 Supplement 19 · Efficacy · priority review LabelLetter
- Apr 25, 2022 Supplement 11 · Efficacy · priority review LetterLabelSummary Review
- Jan 21, 2022 Supplement 10 · Efficacy · priority review LabelLetterSummary Review
- Oct 22, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelSummary ReviewLetterLabel
2 products under this application
- VEKLURY · REMDESIVIR 100MG/20ML (5MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
- VEKLURY · REMDESIVIR 100MG/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Remdesivir" as an intervention, any sponsor and status, largest first.
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)Pivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT04292899 · 4,891 participants · Start Mar 6, 2020 · Primary completion Apr 9, 2020
Drug: Remdesivir; Standard of Care · For: COVID-19
Sites: Anaheim, California; Berkeley, California; Burlingame, California · 183 sites in all
- Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)Pivotal-lookingStatus unknown
ASST Fatebenefratelli SaccoAcademic, hospital or other
NCT04832880 · 4,000 participants (planned) · Start Apr 6, 2021 · Primary completion Mar 2022
Drug: Baricitinib Oral Tablet [Olumiant]; Remdesivir and 1 more · For: Covid19
Sites: Ancona, Italy; Aosta, Italy; Chieti, Italy · 21 sites in all
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Pivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05041907 · 3,800 participants (planned) · Start Sep 30, 2021 · Primary completion Jan 2027
Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™); Nitazoxanide and 16 more · For: COVID-19
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 7 sites in all
- ACTIV-3: Therapeutics for Inpatients With COVID-19Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04501978 · 2,753 participants · Start Aug 4, 2020 · Primary completion Apr 6, 2022
Drug: LY3819253; Placebo and 6 more · For: Covid19
Sites: Tucson, Arizona; Chula Vista, California; Fresno, California · 135 sites in all
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform TrialPivotal-lookingStatus unknown
University of MelbourneAcademic, hospital or other
NCT04483960 · 2,200 participants (planned) · Start Jul 28, 2020 · Primary completion Jul 25, 2025
Drug: (Arm Closed) Nafamostat Mesilate; (Arm Closed) Enoxaparin and 5 more · For: SARS-CoV-2 Infection (COVID-19)
Sites: Blacktown, Australia; Campbelltown, Australia; Darlinghurst, Australia · 25 sites in all
- REMdesivir-HU Clinical Study and Severe Covid-19 PatientsPivotal-lookingStatus unknown
University of PecsAcademic, hospital or other
NCT04610541 · 2,000 participants (planned) · Start Oct 12, 2020 · Primary completion Oct 30, 2021
Drug: Remdesivir-HU · For: SARS-CoV-2 Infection
Sites: Budapest, Hungary; Debrecen, Hungary; Pécs, Hungary · 7 sites in all
- Immune Modulators for Treating COVID-19Pivotal-lookingCompleted
Daniel BenjaminAcademic, hospital or other
NCT04593940 · 1,971 participants · Start Oct 15, 2020 · Primary completion Jan 30, 2022
Drug: Infliximab; Abatacept and 2 more · For: Covid19
Sites: Phoenix, Arizona; Little Rock, Arkansas; La Jolla, California · 91 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,245
- alanine aminotransferase increased935
- covid-19919
- drug ineffective768
- death762
- bradycardia652
- acute kidney injury630
- aspartate aminotransferase increased629
- respiratory failure552
- covid-19 pneumonia505
- liver function test increased422
- condition aggravated396
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 4,479 |
| 2021 | 2,859 |
| 2022 | 2,598 |
| 2023 | 1,647 |
| 2024 | 1,011 |
| 2025 | 536 |
| 2026 | 160 |
Recalls
2 FDA enforcement reports for this application.
Sep 19, 2024 · Class I · Terminated
Presence of Particulate Matter: Presence of glass particle.
Dec 3, 2021 · Class I · Terminated
Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Veklury (Remdesivir)
2024 spending
$381K
Beneficiaries
164
292 claims
Per beneficiary
$2,324
$208.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $253,542 |
| 2023 | $582,565 |
| 2024 | $381,126 |
Part B: Veklury (Remdesivir) · HCPCS J0248
2024 spending
$14.6M
Beneficiaries
7,399
13,477 claims
Per beneficiary
$1,978
2024 ASP limit $6.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $121,749 |
| 2022 | $28,042,110 |
| 2023 | $22,660,480 |
| 2024 | $14,633,667 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [Not Available].
Soto A, Quiñones-Laveriano DM, Garcia PJ, et al. · Rev Peru Med Exp Salud Publica 2020 · Multicenter Study, Randomized Controlled Trial
- Remdesivir for the Treatment of Covid-19 - Final Report.
Beigel JH, Tomashek KM, Dodd LE, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.
Mulangu S, Dodd LE, Davey RT, et al. · N Engl J Med 2019 · Comparative Study, Multicenter Study
- Efficacy of GS-441524 for Feline Infectious Peritonitis: A Systematic Review (2018-2024).
Gokalsing E, Ferrolho J, Gibson MS, et al. · Pathogens 2025 · Systematic Review
- Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.
Ibrahim S, Siemieniuk RAC, Oliveros MJ, et al. · BMJ 2025 · Network Meta-Analysis, Systematic Review
- A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?
Bartoletti M, Mozaffari E, Amin AN, et al. · Clin Infect Dis 2025 · Systematic Review, Meta-Analysis
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.